KRYS
NASDAQKrystal Biotech Inc.
Price$267.88-9.80 (-3.53%)
01:30 PM07:45 PM
News · 26 weeks47-77%
2025-10-262026-04-19
Mix3190d
- SEC Filings12(39%)
- Insider11(35%)
- Other3(10%)
- Earnings3(10%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRKrystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at www.krystalbio.com. A
- SECSEC Form DEFA14A filed by Krystal Biotech Inc.DEFA14A - Krystal Biotech, Inc. (0001711279) (Filer)
- SECSEC Form DEF 14A filed by Krystal Biotech Inc.DEF 14A - Krystal Biotech, Inc. (0001711279) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.SCHEDULE 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
- ANALYSTWolfe Research initiated coverage on Krystal BiotechWolfe Research initiated coverage of Krystal Biotech with a rating of Peer Perform
- PRPalvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient ServicesMs. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut
- INSIDERNew insider Goux Laurent Louis Jean claimed ownership of 919 shares (SEC Form 3)3 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERNew insider Thomas John Charles claimed ownership of 642 shares (SEC Form 3)3 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident, R&D Krishnan Suma sold $6,580,270 worth of shares (25,000 units at $263.21), decreasing direct ownership by 2% to 1,403,155 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident and CEO Krishnan Krish S sold $6,579,164 worth of shares (25,000 units at $263.17), decreasing direct ownership by 2% to 1,475,253 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- INSIDERChief Accounting Officer Romano Kathryn converted options into 8,050 shares, covered exercise/tax liability with 3,502 shares and sold $200,700 worth of shares (750 units at $267.60), increasing direct ownership by 20% to 22,366 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident, R&D Krishnan Suma converted options into 67,225 shares and covered exercise/tax liability with 30,584 shares, increasing direct ownership by 1% to 1,428,155 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident and CEO Krishnan Krish S covered exercise/tax liability with 30,584 shares and converted options into 67,225 shares, increasing direct ownership by 2% to 1,500,253 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERDirector Janney Daniel sold $3,252,824 worth of shares (11,803 units at $275.59) (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- INSIDERDirector Janney Daniel exercised 37,895 shares at a strike of $2.46 and sold $16,149,383 worth of shares (60,161 units at $268.44) (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- PRKrystal Biotech to Present at TD Cowen 46th Annual Health Care ConferencePITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development
- INSIDERDirector Rossi Dino A sold $4,953,694 worth of shares (18,950 units at $261.41) and exercised 18,950 shares at a strike of $8.79 (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)